Elanco Animal Health Past Earnings Performance
Past criteria checks 0/6
Elanco Animal Health's earnings have been declining at an average annual rate of -44.2%, while the Pharmaceuticals industry saw earnings growing at 10.3% annually. Revenues have been growing at an average rate of 10.4% per year.
Key information
-44.2%
Earnings growth rate
-43.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 10.4% |
| Return on equity | -19.8% |
| Net Margin | -27.9% |
| Next Earnings Update | 08 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Elanco Animal Health makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 4,417 | -1,231 | 1,280 | 327 |
| 30 Sep 23 | 4,367 | -1,144 | 1,289 | 328 |
| 30 Jun 23 | 4,324 | -113 | 1,273 | 320 |
| 31 Mar 23 | 4,442 | -26 | 1,263 | 321 |
| 31 Dec 22 | 4,411 | -78 | 1,259 | 321 |
| 30 Sep 22 | 4,538 | -132 | 1,290 | 333 |
| 30 Jun 22 | 4,644 | -171 | 1,334 | 349 |
| 31 Mar 22 | 4,748 | -371 | 1,372 | 361 |
| 31 Dec 21 | 4,764 | -483 | 1,395 | 369 |
| 30 Sep 21 | 4,791 | -698 | 1,431 | 390 |
| 30 Jun 21 | 4,550 | -729 | 1,373 | 384 |
| 31 Mar 21 | 3,857 | -572 | 1,153 | 349 |
| 31 Dec 20 | 3,271 | -574 | 988 | 329 |
| 30 Sep 20 | 2,921 | -246 | 810 | 281 |
| 30 Jun 20 | 2,802 | -101 | 719 | 263 |
| 31 Mar 20 | 2,998 | -13 | 759 | 273 |
| 31 Dec 19 | 3,071 | 68 | 757 | 270 |
| 30 Sep 19 | 3,083 | 94 | 759 | 264 |
| 30 Jun 19 | 3,073 | 144 | 746 | 253 |
| 31 Mar 19 | 3,062 | 45 | 736 | 246 |
| 31 Dec 18 | 3,067 | 87 | 735 | 247 |
| 30 Sep 18 | 3,022 | -91 | 747 | 248 |
| 30 Jun 18 | 2,958 | -172 | 763 | 250 |
| 31 Mar 18 | 2,906 | -174 | 766 | 253 |
| 31 Dec 17 | 2,889 | -311 | 780 | 252 |
| 31 Dec 16 | 2,914 | -48 | 785 | 266 |
| 31 Dec 15 | 2,909 | -211 | 916 | 291 |
Quality Earnings: 5EA is currently unprofitable.
Growing Profit Margin: 5EA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 5EA is unprofitable, and losses have increased over the past 5 years at a rate of 44.2% per year.
Accelerating Growth: Unable to compare 5EA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 5EA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.6%).
Return on Equity
High ROE: 5EA has a negative Return on Equity (-19.78%), as it is currently unprofitable.